Oncotype DX (Genomic Health, Redwood City, CA, USA), a commercially available 21-gene breast cancer recurrence score assay, was recently introduced to predict prognosis in early breast cancer (estrogen receptor-positive/human epidermal growth factor receptor 2-negative/lymph node-negative) patients9. Here, ESR1 is linked to breast carcinoma.